Lamari F, Karamanos N K, Papadopoulou-Alataki E, Kanakoudi-Tsakalidou F, Dimitracopoulos G, Anastassiou E D
Department of Chemistry, University of Patras, Greece.
J Pharm Biomed Anal. 2000 Jul;22(6):1029-36. doi: 10.1016/s0731-7085(00)00297-1.
Patients with antibody deficiency disorders are highly susceptible to bacterial infections. Replacement therapy with intravenous immunoglobulin preparations (IVIG) has been established in such patients for two decades. The efficacy of IVIG treatment depends on the amount of functional pathogen-specific antibodies provided. The present study was undertaken to determine the levels of immunoglobulin classes, IgG subclasses, and specific antibodies to bacterial surface antigens in two different IVIG preparations (Sandoglobulin and Gamimmune) and blood sera of IVIG-treated immunodeficient patients. The levels of IgG, IgA, IgM and IgG subclasses were determined in both IVIG preparations and in patients' sera and were compared with those of healthy individuals. Sandoglobulin contained significantly higher concentrations of IgA, IgG, and IgG4 than Gamimmune. The latter contained higher concentrations of IgG1. Patients treated with Gamimmune) had significantly lower concentration of IgG4 as compared with healthy individuals and Sandoglobulin-treated patients. This finding was related to the preparation's composition. Screening of 20 lots from each preparation for antibodies to frequent clinically isolated strains of Escherichia coli, Staphylococcus aureus, S. epidermidis. Klebsiella pneumoniae and Enterococci spp. showed a high lot-to-lot variability. In order to overcome the lot-to-lot variability and correlate the observed effects with each IVIG preparation, the administered IVIG lots were selected so that their titers were in the interval of mean value +/- S.D. for each pathogen. The two tested preparations showed significant differences in their content of specific antibodies that ultimately affected the levels of these antibodies in treated patients. More specifically, Sandoglobulin contained higher levels of antibodies to E. coli and S. epidermidis strains. Infusion of this preparation maintained the respective antibodies in the recipients significantly higher than those of healthy individuals. Gamimmune infusion led to similar and comparable levels. Both IVIG preparations had comparable antibody titers towards K. pneumoniae, provided high amounts of antibodies, and kept recipients' specific IgG at levels significantly higher than those of the healthy individuals. Enterococci spp. specific antibodies were significantly higher in Gamimmune, whereas titers of antibodies towards S. aureus were comparable. Levels of antibodies against both Enterococci spp. and S. epidermidis after administration of both preparations were close to those in healthy individuals. None of the patients developed infection during the time of the study. In conclusion, most of the lots of the two IVIG preparations studied, despite some quantitative differences, provide patients with sufficient amounts of antibodies to bacterial surface antigens that protect them against infections.
抗体缺乏症患者极易受到细菌感染。静脉注射免疫球蛋白制剂(IVIG)替代疗法已在此类患者中应用了二十年。IVIG治疗的疗效取决于所提供的功能性病原体特异性抗体的量。本研究旨在测定两种不同的IVIG制剂(Sandoglobulin和Gamimmune)以及接受IVIG治疗的免疫缺陷患者血清中免疫球蛋白类别、IgG亚类和细菌表面抗原特异性抗体的水平。测定了两种IVIG制剂和患者血清中IgG、IgA、IgM及IgG亚类的水平,并与健康个体进行比较。Sandoglobulin中IgA、IgG和IgG4的浓度明显高于Gamimmune。后者含有较高浓度的IgG1。与健康个体和接受Sandoglobulin治疗的患者相比,接受Gamimmune治疗的患者IgG4浓度显著较低。这一发现与制剂的成分有关。对每种制剂的20批产品进行针对临床常见分离株大肠杆菌、金黄色葡萄球菌、表皮葡萄球菌、肺炎克雷伯菌和肠球菌属的抗体筛选,结果显示批次间差异很大。为了克服批次间差异并将观察到的效果与每种IVIG制剂相关联,选择所使用的IVIG批次,使其针对每种病原体的效价处于平均值±标准差范围内。两种受试制剂在特异性抗体含量上存在显著差异,并最终影响了治疗患者体内这些抗体的水平。更具体地说:Sandoglobulin含有较高水平针对大肠杆菌和表皮葡萄球菌菌株的抗体。输注该制剂后受者体内相应抗体水平显著高于健康个体。输注Gamimmune后导致类似且相当的水平。两种IVIG制剂针对肺炎克雷伯菌的抗体效价相当,提供了大量抗体,并使受者的特异性IgG水平显著高于健康个体。Gamimmune中肠球菌属特异性抗体明显更高,而针对金黄色葡萄球菌的抗体效价相当。两种制剂给药后针对肠球菌属和表皮葡萄球菌的抗体水平均接近健康个体。在研究期间,没有患者发生感染。总之,尽管存在一些数量差异,但所研究的两种IVIG制剂的大多数批次都为患者提供了足够量针对细菌表面抗原的抗体,从而保护他们免受感染。